Deramciclane

Identification

Name
Deramciclane
Accession Number
DB06512
Type
Small Molecule
Groups
Investigational
Description

Deramciclane (EGIS-3886) is a non-benzodiazepine-type anxiolytic drug to treat various types of anxiety disorders. Deramciclane is a unique alternative to current anxiolytics on the market because it has a novel chemical structure and target. It acts as an antagonist at the 5-HT2A receptor, as an inverse agonist at the 5-HT2C receptor, and as a GABA reuptake inhibitor.

Structure
Thumb
Synonyms
Not Available
External IDs
EGIS-3886 / EGYT 3886 / EGYT-3886 / EGYT3886
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
O5KFK61E74
CAS number
120444-71-5
Weight
Average: 301.474
Monoisotopic: 301.240564622
Chemical Formula
C20H31NO
InChI Key
QOBGWWQAMAPULA-RLLQIKCJSA-N
InChI
InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
IUPAC Name
dimethyl(2-{[(1R,2S,4R)-1,7,7-trimethyl-2-phenylbicyclo[2.2.1]heptan-2-yl]oxy}ethyl)amine
SMILES
[H][C@]12CC[C@](C)(C1(C)C)[C@@](C2)(OCCN(C)C)C1=CC=CC=C1

Pharmacology

Indication

Investigated for use/treatment in anxiety disorders.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action

Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties.

TargetActionsOrganism
U5-hydroxytryptamine receptor 2A
antagonist
Human
U5-hydroxytryptamine receptor 2C
inverse agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with deramciclane.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with deramciclane.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with deramciclane.Approved
AdipiplonThe risk or severity of adverse effects can be increased when deramciclane is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when deramciclane is combined with Agomelatine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when deramciclane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with deramciclane.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when deramciclane is combined with Sage 547.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with deramciclane.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with deramciclane.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with deramciclane.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when deramciclane is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with deramciclane.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when deramciclane is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when deramciclane is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with deramciclane.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with deramciclane.Approved
AzaperoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Azaperone.Vet Approved
Azelastinederamciclane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when deramciclane is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when deramciclane is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with deramciclane.Illicit
BenperidolThe risk or severity of adverse effects can be increased when deramciclane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with deramciclane.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when deramciclane is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when deramciclane is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with deramciclane.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when deramciclane is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with deramciclane.Approved, Investigational
Buprenorphinederamciclane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with deramciclane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with deramciclane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when deramciclane is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when deramciclane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with deramciclane.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with deramciclane.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with deramciclane.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when deramciclane is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with deramciclane.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when deramciclane is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when deramciclane is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with deramciclane.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with deramciclane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with deramciclane.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with deramciclane.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when deramciclane is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with deramciclane.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with deramciclane.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with deramciclane.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when deramciclane is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when deramciclane is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when deramciclane is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when deramciclane is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with deramciclane.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when deramciclane is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with deramciclane.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with deramciclane.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with deramciclane.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with deramciclane.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when deramciclane is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with deramciclane.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when deramciclane is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with deramciclane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when deramciclane is combined with Dapoxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with deramciclane.Approved
DesipramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when deramciclane is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when deramciclane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with deramciclane.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with deramciclane.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with deramciclane.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with deramciclane.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with deramciclane.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when deramciclane is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with deramciclane.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with deramciclane.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with deramciclane.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when deramciclane is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with deramciclane.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with deramciclane.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when deramciclane is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when deramciclane is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when deramciclane is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with deramciclane.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when deramciclane is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with deramciclane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with deramciclane.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when deramciclane is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when deramciclane is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when deramciclane is combined with Pregnanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with deramciclane.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when deramciclane is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when deramciclane is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with deramciclane.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with deramciclane.Approved
Ethanolderamciclane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with deramciclane.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when deramciclane is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with deramciclane.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with deramciclane.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with deramciclane.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when deramciclane is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when deramciclane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with deramciclane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with deramciclane.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when deramciclane is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when deramciclane is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with deramciclane.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with deramciclane.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when deramciclane is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when deramciclane is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with deramciclane.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when deramciclane is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with deramciclane.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with deramciclane.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with deramciclane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with deramciclane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with deramciclane.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when deramciclane is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with deramciclane.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when deramciclane is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when deramciclane is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with deramciclane.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when deramciclane is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with deramciclane.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when deramciclane is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with deramciclane.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when deramciclane is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with deramciclane.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with deramciclane.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with deramciclane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with deramciclane.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with deramciclane.Approved
Hydrocodonederamciclane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with deramciclane.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved
IloperidoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when deramciclane is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with deramciclane.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with deramciclane.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with deramciclane.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when deramciclane is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when deramciclane is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with deramciclane.Approved
LevocabastineThe risk or severity of adverse effects can be increased when deramciclane is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when deramciclane is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when deramciclane is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with deramciclane.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when deramciclane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with deramciclane.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with deramciclane.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with deramciclane.Approved
LofentanilThe risk or severity of adverse effects can be increased when deramciclane is combined with Lofentanil.Illicit
LoratadineThe risk or severity of adverse effects can be increased when deramciclane is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with deramciclane.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with deramciclane.Approved
LurasidoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when deramciclane is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when deramciclane is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of deramciclane can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with deramciclane.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with deramciclane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with deramciclane.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with deramciclane.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when deramciclane is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with deramciclane.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with deramciclane.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with deramciclane.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with deramciclane.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when deramciclane is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with deramciclane.Approved
Methotrimeprazinederamciclane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with deramciclane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when deramciclane is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with deramciclane.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with deramciclane.Approved
Metyrosinederamciclane may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of deramciclane can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with deramciclane.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when deramciclane is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Investigational
Mirtazapinederamciclane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with deramciclane.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with deramciclane.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with deramciclane.Approved
NefazodoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with deramciclane.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when deramciclane is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when deramciclane is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when deramciclane is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with deramciclane.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when deramciclane is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with deramciclane.Approved
OpiumThe risk or severity of adverse effects can be increased when deramciclane is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of deramciclane can be decreased when it is combined with Orlistat.Approved, Investigational
Orphenadrinederamciclane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with deramciclane.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with deramciclane.Approved
OxethazaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with deramciclane.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with deramciclane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with deramciclane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with deramciclane.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with deramciclane.Approved
Paraldehydederamciclane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when deramciclane is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with deramciclane.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with deramciclane.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved
PerazineThe risk or severity of adverse effects can be increased when deramciclane is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when deramciclane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with deramciclane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with deramciclane.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with deramciclane.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when deramciclane is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when deramciclane is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with deramciclane.Approved
PipamperoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when deramciclane is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when deramciclane is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when deramciclane is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when deramciclane is combined with Pomalidomide.Approved
Pramipexolederamciclane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with deramciclane.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with deramciclane.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with deramciclane.Approved
PrimidoneThe risk or severity of adverse effects can be increased when deramciclane is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with deramciclane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with deramciclane.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with deramciclane.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when deramciclane is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with deramciclane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with deramciclane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when deramciclane is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when deramciclane is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with deramciclane.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with deramciclane.Approved
RacloprideThe risk or severity of adverse effects can be increased when deramciclane is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when deramciclane is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with deramciclane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with deramciclane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with deramciclane.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with deramciclane.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when deramciclane is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Romifidine.Vet Approved
Ropinirolederamciclane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with deramciclane.Approved
Rotigotinederamciclane may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with deramciclane.Approved
ScopolamineThe risk or severity of adverse effects can be increased when deramciclane is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with deramciclane.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when deramciclane is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with deramciclane.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when deramciclane is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with deramciclane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved
StiripentolThe risk or severity of adverse effects can be increased when deramciclane is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with deramciclane.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with deramciclane.Approved
Suvorexantderamciclane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when deramciclane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Approved
TasimelteonThe risk or severity of adverse effects can be increased when deramciclane is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with deramciclane.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when deramciclane is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when deramciclane is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with deramciclane.Investigational
Thalidomidederamciclane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with deramciclane.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with deramciclane.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with deramciclane.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with deramciclane.Approved
TiagabineThe risk or severity of adverse effects can be increased when deramciclane is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when deramciclane is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when deramciclane is combined with Tiletamine.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when deramciclane is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when deramciclane is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with deramciclane.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with deramciclane.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with deramciclane.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with deramciclane.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with deramciclane.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with deramciclane.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with deramciclane.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when deramciclane is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with deramciclane.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when deramciclane is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when deramciclane is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when deramciclane is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when deramciclane is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of deramciclane can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with deramciclane.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when deramciclane is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when deramciclane is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with deramciclane.Approved
ZolazepamThe risk or severity of adverse effects can be increased when deramciclane is combined with Zolazepam.Vet Approved
Zolpidemderamciclane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when deramciclane is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with deramciclane.Approved
ZotepineThe risk or severity of adverse effects can be increased when deramciclane is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with deramciclane.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
  1. Kovacs I, Maksay G, Simonyi M: Inhibition of high-affinity synaptosomal uptake of gamma-aminobutyric acid by a bicyclo-heptane derivative. Arzneimittelforschung. 1989 Mar;39(3):295-7. [PubMed:2502985 ]
External Links
ChemSpider
106785
ChEMBL
CHEMBL2104698
Wikipedia
Deramciclane
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00103 mg/mLALOGPS
logP5.22ALOGPS
logP4.3ChemAxon
logS-5.5ALOGPS
pKa (Strongest Basic)8.87ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity92.59 m3·mol-1ChemAxon
Polarizability36.46 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Prenol lipids
Sub Class
Monoterpenoids
Direct Parent
Bicyclic monoterpenoids
Alternative Parents
Aromatic monoterpenoids / Benzylethers / Trialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aromatic monoterpenoid / Bornane monoterpenoid / Bicyclic monoterpenoid / Benzylether / Monocyclic benzene moiety / Benzenoid / Tertiary amine / Tertiary aliphatic amine / Ether / Dialkyl ether
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Kanerva H, Vilkman H, Nagren K, Kilkku O, Kuoppamaki M, Syvalahti E, Hietala J: Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. Psychopharmacology (Berl). 1999 Jul;145(1):76-81. [PubMed:10445375 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Palvimaki EP, Majasuo H, Kuoppamaki M, Mannisto PT, Syvalahti E, Hietala J: Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104. [PubMed:9551765 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Laine K, De Bruyn S, Bjorklund H, Rouru J, Hanninen J, Scheinin H, Anttila M: Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Eur J Clin Pharmacol. 2004 Feb;59(12):893-8. Epub 2004 Jan 17. [PubMed:14730412 ]
Drug created on March 19, 2008 10:35 / Updated on September 01, 2017 11:28